Humanigen Inc (HGENQ)

[cowtown jay]

I hinted about my expectation in this regard.

"A $1M per patient treatment cost, and the treatment is ineffective for 30% of the treated patients.

Sounds like a job for lenzilumab.

But surely not, right? How could lenz possibly eliminate most of the treatment cost, and also improve the complete response rate for patients, when Humanigen's stock price it teetering on one cent?

Dare I to think that this unrealized potential presents promise almost beyond comprehension? Could share price be transient, yet result in lenzilumab demonstrating results that are robust and durable?

This is just about one of the many active opportunities for lenz. I'm here for the realization of all of lenzilumab's opportunities.

And political power is not a factor for this indication. Nor does Big Pharma regulatory influence come into play. When a product is as good as lenz, it can't be denied for everything, and forever."

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172881158

This is actually about TeraImmune's 'TI-168.' We've seen proof of our interest in Baudax/TeraImmune through our investment. However, I haven't seen evidence of lenz enabling TI-168 to perform so well, so I didn't say more than I did.

https://investorplace.com/2023/09/why-is-baudax-bio-bxrx-stock-up-75-today/